Recent Articles

Found 63 Results
Page 2 of 7

Immuneering to Present at the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting

CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) — Immuneering today announced the company’s participation in the 12th International Conference on Cachexia, Sarcopenia & Muscle Wasting taking place in Berlin, Dec. 6-8,…


Advances in Computational Toxicology – Methodologies and Applications in Regulatory Science

Excerpt from Chapter 1 – Computational Toxicology Promotes Regulatory Science: New tools have become available to researchers and regulators including genomics, transcriptomics, proteomics, machine learning, artificial intelligence, molecular dynamics, bioinformatics,…


Realizing the promise of computational prediction in toxicology applications

Toxicant screening is only as efficient and effective as the underlying methods. Unfortunately, chemical toxicity screening is predominated by slow, laborious, and costly methods some of which raise ethical concerns….


Similarities and differences between variants called with human reference genome HG19 or HG38

Reference genome selection is a prerequisite for successful analysis of next generation sequencing (NGS) data. Current practice employs one of the two most recent human reference genome versions: HG19 or…


Computational prediction models for assessing endocrine disrupting potential of chemicals

Endocrine disrupting chemicals (EDCs) mimic natural hormones and disrupt endocrine function. Humans and wildlife are exposed to EDCs might alter endocrine functions through various mechanisms and lead to an adverse…


Evotec and Immuneering to collaborate on artificial intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases

Hamburg, Germany, and Cambridge, USA, 21 November 2018: Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that it has entered into a research collaboration with Immuneering Corporation…


The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer’s disease

Cambridge, MA and London, 18 June 2018 – The Dementia Discovery Fund (“DDF”) and Immuneering Corporation (“Immuneering”) today announce they have entered into a joint research collaboration to identify novel drug targets…


Immuneering CEO Ben Zeskind to speak at 4th Cancer Cachexia Conference

June 11th, 2018 — Immuneering’s CEO (Ben Zeskind) is scheduled to present an invited talk entitled “Data-driven identification and optimization of new medicines for cancer cachexia” at the 4th Cancer…


Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone

For more than 20 years, Copaxone (glatiramer acetate, Teva), a non-biological complex drug, has been a safe and effective treatment option for multiple sclerosis. In 2016, a follow-on glatiramer acetate…


Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

Huntington Disease (HD) is an incurable autosomal dominant neurodegenerative disorder driven by an expansion repeat giving rise to the mutant huntingtin protein (mHtt), which is known to disrupt a multitude…


Page 2 of 7